LRRK2 Kinase Activity in Parkinson's Disease

Leucine-rich repeat kinase 2 (LRRK2) is a multi-domain serine/threonine kinase implicated in both familial and sporadic forms of Parkinson’s disease. Pathogenic variants in the LRRK2 gene elevate its catalytic activity, leading to aberrant phosphorylation of downstream substrates and disruption of intracellular pathways. Among these substrates, Rab GTPases have emerged as central mediators of vesicular trafficking, primary cilia formation, organelle homeostasis and immune responses. Enhanced LRRK2 kinase activity has been linked to deficits in axonal transport, lysosomal function and neuroinflammation, all of which contribute to dopaminergic neuronal loss in the substantia nigra. The pathogenic G2019S mutation, the most prevalent, intensifies kinase activity by two- to threefold, while other mutations alter GTPase function and subcellular localisation. Therapeutic strategies targeting LRRK2 aim to normalise kinase activity, restore cellular transport dynamics and attenuate inflammatory cascades. Preclinical models demonstrate that modulation of microtubule acetylation can reverse transport impairments caused by hyperactive LRRK2, and that selective kinase inhibition mitigates progression of tau and synuclein pathologies. Ongoing clinical trials of LRRK2 inhibitors incorporate novel pharmacodynamic biomarkers to assess target engagement and inform patient stratification, offering a promising route towards disease modification.

Research from Nature Portfolio

Recent studies have demonstrated that pathogenic Roc-COR domain mutations in LRRK2 preferentially bind to deacetylated microtubules, disrupting axonal transport in neurons and in vivo models. By enhancing microtubule acetylation through pharmacological inhibition of deacetylases or overexpression of acetylases, normal axonal trafficking and locomotor function are restored. These findings establish microtubule acetylation as a modifiable determinant of LRRK2-induced transport deficits and suggest deacetylase inhibitors as potential therapeutic adjuncts to kinase inhibitors.

LRRK2 Kinase Activity in Parkinson's Disease publication trend

The graph below shows the total number of articles in lrrk2 kinase activity in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

LRRK2 kinase: An enzyme that transfers phosphate groups to serine or threonine residues of target proteins, modulating their function.

Rab GTPases: A family of small GTP-binding proteins that regulate vesicular trafficking and membrane dynamics.

Microtubule acetylation: A post-translational modification of α-tubulin that enhances microtubule stability and supports axonal transport.

Axonal transport: The bidirectional movement of organelles, proteins and vesicles along neuronal axons, essential for neuronal survival.

Phosphorylation: A reversible modification in which a kinase adds a phosphate group to a protein, altering its activity or interactions.

References

1. RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses. The Lancet Neurology (2024).
2. Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammation. Molecular Neurodegeneration (2024).
3. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression. Translational Neurodegeneration (2024).
4. Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nature Communications (2014).
5. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration*. Journal of Biological Chemistry (2015).
6. Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis. eLife (2017).
7. The role of the LRRK2 gene in Parkinsonism. Molecular Neurodegeneration (2014).